文献速递血栓与止血

首次不明原因静脉血栓栓塞事件后重启抗凝治疗策略的经济学评价

Economic evaluation of strategies for restarting anticoagulation therapy after a first event of unprovoked venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2017-07-11

该研究构建马尔可夫患者水平模拟模型,从英国国家卫生服务体系/个人社会服务视角评价基于复发风险的决策规则指导重启抗凝与不延长治疗的成本效果。基础病例模型显示,预测1年VTE风险≥17.5%的患者重启抗凝在支付意愿≤20000英镑/QALY时可能具有成本效果,但概率敏感性分析显示模型对参数不确定性高度敏感。

要点

  • 预测1年VTE风险≥17.5%的患者重启抗凝在20000英镑/QALY阈值下可能具有成本效果。
  • 概率敏感性分析显示模型对总体参数不确定性高度敏感,基于成本效果选择最优决策规则需谨慎。
  • 抗凝治疗负效用和死亡风险等变量对模型结果影响很大。

核心结论

  • 基础病例模型结果提示,对预测1年VTE风险≥17.5%的患者重启抗凝治疗,若决策者愿意支付至20000英镑/QALY,可能具有成本效果。
  • 概率敏感性分析显示模型对总体参数不确定性高度敏感,基于成本效果选择最优决策规则需谨慎。
  • 这是首个考虑使用决策规则为不明原因VTE患者重启治疗的经济学模型。
  • 需要更好的数据来预测该患者群体治疗期间的长期出血风险。

研究设计与样本

  • 开发了马尔可夫患者水平模拟模型,采用终身时间跨度、月度时间周期,从英国国家卫生服务体系/个人社会服务视角进行经济学评价。
  • 比较基于进一步不明原因VTE风险使用决策规则重启抗凝治疗与不延长治疗策略。

主要发现

  • 基础病例模型结果提示,治疗预测1年VTE风险≥17.5%或更高的患者,若决策者愿意支付至20000英镑/QALY,可能具有成本效果。
  • 概率敏感性分析显示模型对总体参数不确定性高度敏感。
  • 单变量敏感性分析表明抗凝治疗负效用和死亡风险等变量对模型结果影响很大。

关键数值与推荐

  • 预测1年VTE风险≥17.5%的患者重启抗凝治疗,在支付意愿至20000英镑/QALY时可能具有成本效果。

局限性

  • 概率敏感性分析显示模型对总体参数不确定性高度敏感,基于成本效果选择最优决策规则需谨慎。
  • 需要更好的数据来预测该患者群体治疗期间的长期出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Correct duration of treatment after a first unprovoked venous thromboembolism (VTE) is unknown. We assessed when restarting anticoagulation was worthwhile based on patient risk of recurrent VTE. When the risk over a one-year period is 17.5%, restarting is cost-effective. However, sensitivity analyses indicate large uncertainty in the estimates. SUMMARY: Background Following at least 3 months of anticoagulation therapy after a first unprovoked venous thromboembolism (VTE), there is uncertainty about the duration of therapy. Further anticoagulation therapy reduces the risk of having a potentially fatal recurrent VTE but at the expense of a higher risk of bleeding, which can also be fatal. Objective An economic evaluation sought to estimate the long-term cost-effectiveness of using a decision rule for restarting anticoagulation therapy vs. no extension of therapy in patients based on their risk of a further unprovoked VTE. Methods A Markov patient-level simulation model was developed, which adopted a lifetime time horizon with monthly time cycles and was from a UK National Health Service (NHS)/Personal Social Services (PSS) perspective. Results Base-case model results suggest that treating patients with a predicted 1 year VTE risk of 17.5% or higher may be cost-effective if decision makers are willing to pay up to £20 000 per quality adjusted life year (QALY) gained. However, probabilistic sensitivity analysis shows that the model was highly sensitive to overall parameter uncertainty and caution is warranted in selecting the optimal decision rule on cost-effectiveness grounds. Univariate sensitivity analyses indicate variables such as anticoagulation therapy disutility and mortality risks were very influential in driving model results. Conclusion This represents the first economic model to consider the use of a decision rule for restarting therapy for unprovoked VTE patients. Better data are required to predict long-term bleeding risks during therapy in this patient group.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Monahan M, Ensor J, Moore D, et al. Economic evaluation of strategies for restarting anticoagulation therapy after a first event of unprovoked venous thromboembolism. J Thromb Haemost. 2017. PMID: 28520199. doi:10.1111/jth.13739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。